RxDoctor Payments Data

Sumedha Sonde, MD

Pulmonary Disease · Dalton, GANPI 1750886339

Payments from drug & device makers

$6,429in general payments, 2019–2025

Across 77 payments — averaging $83.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Olympus Corporation Of The Americas$318
  • Boehringer Ingelheim$278
  • United Therapeutics Corporation$146
  • Actelion Pharmaceuticals US, Inc.$132
  • Viatris Specialty LLC$117
  • plus $790 from 19 others

What the payments were for

  • Travel & lodging$5458%
  • Food & beverage$1,80428%
  • Education$4,08063%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,429 in reported general payments places this provider in the 55th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$25,469
Medicare patients
97
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$42,718
Incruse ElliptaUmeclidinium Bromide40$15,761
Spiriva HandihalerTiotropium Bromide21$13,478
Breo ElliptaFluticasone/Vilanterol22$10,838
Combivent RespimatIpratropium/Albuterol Sulfate18$8,587
Albuterol Sulfate HfaAlbuterol Sulfate104$3,559
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,174
SymbicortBudesonide/Formoterol Fumarate16$3,098
Varenicline Tartrate13$2,355
Wixela InhubFluticasone Propion/Salmeterol12$2,210
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,596
Montelukast Sodium43$265
Prednisone47$65
Azithromycin23$58
Pantoprazole Sodium14$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$82$69,317122 claims
Boehringer IngelheimCombivent Respimat$278$8,58718 claims
AstraZenecaSymbicort$15$3,09816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →